Myriad Genetics, Inc.
Myriad Genetics, Inc. (MYGN) Financial Performance & Income Statement Overview
Explore the financials of Myriad Genetics, Inc. (MYGN), including yearly and quarterly data on income, cash flow, and balance sheets.
Myriad Genetics, Inc. (MYGN) Income Statement & Financial Overview
Review Myriad Genetics, Inc. MYGN income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $195.90M | $210.60M | $213.30M | $211.50M |
| Cost of Revenue | $61.70M | $59.70M | $63.50M | $64.40M |
| Gross Profit | $134.20M | $150.90M | $149.80M | $147.10M |
| Gross Profit Ratio | $0.69 | $0.72 | $0.70 | $0.70 |
| R&D Expenses | $27.50M | $32.20M | $28.50M | $27.10M |
| SG&A Expenses | $135.70M | $136.00M | $139.10M | $144.90M |
| Operating Expenses | $163.20M | $189.90M | $169.80M | $183.60M |
| Total Costs & Expenses | $224.90M | $249.60M | $233.30M | $248.00M |
| Interest Income | $300000.00 | $300000.00 | $400000.00 | $400000.00 |
| Interest Expense | $800000.00 | $700000.00 | $800000.00 | $800000.00 |
| Depreciation & Amortization | $14.40M | $14.80M | $15.60M | $15.10M |
| EBITDA | -$14.20M | -$23.60M | -$2.20M | -$21.20M |
| EBITDA Ratio | -$0.07 | -$0.11 | -$0.01 | -$0.10 |
| Operating Income | -$29.00M | -$39.00M | -$20.00M | -$36.50M |
| Operating Income Ratio | -$0.15 | -$0.19 | -$0.09 | -$0.17 |
| Other Income/Expenses (Net) | -$400000.00 | -$100000.00 | -$1.20M | -$700000.00 |
| Income Before Tax | -$29.40M | -$39.10M | -$21.20M | -$37.20M |
| Income Before Tax Ratio | -$0.15 | -$0.19 | -$0.10 | -$0.18 |
| Income Tax Expense | -$29.30M | $3.40M | $900000.00 | -$500000.00 |
| Net Income | -$100000.00 | -$42.50M | -$22.10M | -$36.70M |
| Net Income Ratio | -$0.001 | -$0.20 | -$0.10 | -$0.17 |
| EPS | -$0.001 | -$0.47 | -$0.24 | -$0.41 |
| Diluted EPS | -$0.001 | -$0.47 | -$0.24 | -$0.41 |
| Weighted Avg Shares Outstanding | $91.40M | $91.10M | $90.90M | $90.60M |
| Weighted Avg Shares Outstanding (Diluted) | $91.40M | $91.10M | $90.90M | $90.60M |
Over the last four quarters, Myriad Genetics, Inc. achieved steady financial progress, growing revenue from $211.50M in Q2 2024 to $195.90M in Q1 2025. Gross profit stayed firm with margins at 69% in Q1 2025 versus 70% in Q2 2024. Operating income totaled -$29.00M in Q1 2025, maintaining a -15% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$14.20M. Net income rose to -$100000.00, with EPS at -$0.001. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan